Investing.com — 在动荡的市场环境中，GYRE股票面临重大阻力，目前交易价格为6.46美元，仅略高于其52周低点6.17美元。 InvestingPro ...

Investing.com — 在动荡的市场环境中，GYRE股票已达到新的52周低点，触及8.26美元。根据 InvestingPro ...

In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales & Marketing costs, amounting to US$57.5m (64% of total expenses ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary ...

One of the ocean currents in the Arctic Ocean is at risk of disappearing this century because of climate change, according to ...

A major ocean current in the Arctic, the Beaufort Gyre, is changing rapidly due to climate warming—and this could trigger a ...

Gyre Therapeutics Inc. SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis ...

When the Kīlauea Volcano erupted in May 2018, an enormous amount of ash was released into the atmosphere in a plume nearly ...

Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has ...